Publication

Article

CURE

Lung Cancer Special Issue (2)
Volume2
Issue 1

Investigational Drug Shows Promise in Patients with RET-Altered Cancers

Author(s):

Patients with RET-fusion-positive non-small cell lung cancer (NSCLC) had a high response to LOXO-292 (selpercatinib), according to findings from the largest clinical trial of patients with RET-altered cancers.

Patients with RET-fusion-positive non-small cell lung cancer (NSCLC) had a high response to LOXO-292 (selpercatinib), according to findings from the largest clinical trial of patients with RET-altered cancers.

The oral investigational medication was examined in 105 patients who had a median of three prior treatment regimens. LOXO-292 showed a 68% objective response rate, meaning their tumors shrunk by at least 30%.

“In this large cohort, selpercatinib’s response rate, durability, robust CNS (central nervous system) activity and safety show promise,” Dr. Alexander Drilon, the lead investigator and a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, said in a press release. “Furthermore, this continues to confirm that RET fusions are clinically targetable alterations, placing them in the company of activating EGFR/ALK/ROS1 alterations.”

RET fusions, rare genetic alterations of NSCLC, occur in roughly 2% of NSCLC cases. Up to 50% of these cancers can spread to the brain.

LOXO-292 was well-tolerated by patients. A safety analysis that included all 531 patients enrolled in the trial showed that nine patients stopped treatment because of a therapy-related side effect. The most common side effects included dry mouth, diarrhea, hypertension, increased liver enzymes, fatigue, constipation and headache.

Newsletter

Stay up to date on cancer updates, research and education